Erlotinib in previously treated non-small-cell lung cancer

• Main Authors: Frances A. Shepherd, José Rodrigues Pereira, Tudor Ciuleanu, Huat Tan Eng, Vera Hirsh, Sumitra Thongprasert, Daniel Campos, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, M. Van Kooten, Mircea Dediu, Brian Findlay, Dongsheng Tu, Dianne Johnston, Andrea Bezjak, Gary Clark, Pedro Santabárbara, Lesley Seymour
• Format: Journal
• Published: 2018
• Subjects: Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=22044445517&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/62363
• Institution: Chiang Mai University

BACKGROUND: We conducted a randomized, placebo-controlled, double-blind trial to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy. METHODS: Patients with stage IIIB o...